2.23% Aug 29, 08:48 PM
$1.17 Paid Quarterly
23.7% EPS $4.93
1 year Since 2013
No Ex-Dividend Dates
Have Been Scheduled

TEVA - Upcoming Dividend Payouts
Next Ex-Dividend Date None

Amount Declare Date Ex-Dividend Date ▲ Record Date Pay Date Payout Type
$0.2911 2014-08-19 2014-08-21 2014-09-04 Regular
Date has passed
Next Ex-Dividend Date
Next Pay Date
TEVA has not yet officially announced its next dividend payout.

TEVA - Dividend Yield & Stock Price History
Current Dividend Yield 2.23%

Arrow-right
5y
All

TEVA - Dividend Payout History
Current Annual Payout $1.17

5y
All
Dividend payouts are split-adjusted

TEVA - Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal Dividend Growth History for TEVA. 17.6% 35.1% 1 year
Annual dividend amounts based on Ex-dividend date

TEVA - Historical Annual Dividend Data & Growth
Payouts Increasing For 1 year

Payout Amount Calendar Year Annual Growth
$1.0863 2013 35.1%
$0.8039 2012 -18.3%

TEVA - Historical Dividend Data
Payouts Increasing For 1 year

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.2911 2014-08-19 2014-08-21 2014-09-04 Unknown Regular Quarter
$0.2978 2014-05-16 2014-05-20 2014-06-02 Unknown Regular Quarter
$0.2930 2014-02-20 2014-02-24 2014-03-10 Unknown Regular Quarter
$0.2775 2013-11-18 2013-11-20 2013-12-03 Unknown Regular Quarter
$0.2737 2013-08-16 2013-08-20 2013-09-03 Unknown Regular Quarter

Teva Pharmaceutical Industries Ltd (TEVA) - News

  • Teva Pharmaceutical to Cut 5,000 Jobs (TEVA)

    Teva Pharmaceutical Industries Ltd (TEVA) announced on Thursday that it plans to cut 5,000 jobs in an effort to reduce costs. The pharmaceutical company stated that cutting 5,000 jobs, which accounts for 10% of its workforce, will save the company an estimated $2 billion a year. These cuts are a part of the company's cost-cutting goals, which it hopes to achieve by the end of 2017. Teva estimates that roughly $1 billion will be saved by the end of 2014, and the remaining 70% would come by the end of 2015. This comes after CEO Jeremy Levin vowed in December that the company would reduce annual costs by $1.5 billion to $2 billion over five years. Teva Pharmaceutical shares rallied 3.38% during Thursday's session. Year-to-date, the stock is up 5.40%.

    The Bottom Line

    Shares of Teva Pharmaceutical Industries Ltd (TEVA) currently yield 2.69% based on Thursday's closing price of $40.57 and its annual payout of $1.09. Teva Pharmaceutical Industries Ltd (TEVA)  is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.2 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • Teva Acquires MicroDose Therapeutx (TEVA)

    Today, Teva Pharmaceuticals (TEVA) announced the purchase of MicroDose Therapeutx for $40M. The Israel-based firm made the move in order to expand its line-up of respiratory products. MicroDose, a private firm, focuses on inhalation technologies to treat lung ailments. Investors should note that as a part of the deal, Teva may pay up to $125 million if certain developmental targets are met. Teva is currently the largest generic drug manufacturer in the world and trades on both the NYSE and the Tel Aviv Stock Exchange. Teva shares were up $0.24 or 0.61% at Monday's close. The stock is currently 8% off of its 52-week highs. The Bottom Line Shares of Teva Pharmaceuticals (TEVA) have a yield of 2.77% based on Monday's closing price of $39.32. Teva Pharmaceuticals (TEVA) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.2 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Lennar Corp...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Teva...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Teva...
  • Teva Pharmaceutical's Numbers Cut at Needham & Co. (TEVA)

    Israeli drug maker Teva Pharmaceutical Industries Ltd (TEVA) on Friday caught some tepid commentary from analysts at Needham & Company. The firm maintained its "Hold" rating on TEVA but lowered its 2012 EPS estimate from $5.59 to $5.34, and its 2013 EPS estimate from $6.01 to $5.70. A Needham analyst commented, "A quick two weeks post effectively withdrawing 2012 financial guidance, new Teva management emerged with updated near-term financial objectives that while differing only marginally from prior guidance in the aggregate, clearly set a floor under the 'how bad can it be' thinking that has hung over shares post 1Q12 results. Given current state of sentiment in the name with shares plunging the depths of oversold territory reached on only four occasions in the past decade, a reflex rally is overdue though key structural overhangs, longer-term opacity on evolution of growth initiatives and revamping of strategic priorities, we find little compelling reason to support a significant fundamental outperformance thesis." Teva shares were unchanged in premarket trading Friday. The Bottom Line Shares of Teva Pharmaceuticals (TEVA) have a 2.77% dividend yield, based on last night's closing stock price of $38.69. The stock has technical support in the $35-$36 price area. If the shares can firm up, we see overhead resistance around the $42 price level. Teva Pharmaceutical Industries Ltd (TEVA) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.2 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights International...
  • Teva Pharmaceuticals to Buy Cephalon for $6.8 Billion in Cash (TEVA)

    Israeli drugmaker Teva Pharmaceutical Industries Ltd (TEVA) on Monday announced it would acquire rival pharma company Cephalon (CEPH) for $6.8 billion in cash. The agreed-upon deal marks the end of Valeant Pharmaceuticals' (VRX) hostile bid for Cephalon. Valeant had bid $73, which Cephalon's board rejected as undervaluing the company. Teva will pay $81.50 for CEPH, which marks a 6% upside from the stock's Friday closing price of $77.02. The deal is expected to close in the third quarter. Teva Pharmaceuticals shares rose $1.57, or +3.4%, in premarket trading Monday. The Bottom Line Shares of Teva Pharmaceuticals (TEVA) have a 1.88% dividend yield, based on Friday's closing stock price of $45.73. The stock has technical support in the $40-$42 price area. If the shares can firm up, we see overhead resistance around the $48-$50 price levels. Teva Pharmaceutical Industries Ltd (TEVA) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Diamond Foods...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Enterprise GP...
Top-5-pitch